AU2013366450A1 - Immunogenic composition comprising elements of C. difficile CDTb and/or CDTa proteins - Google Patents
Immunogenic composition comprising elements of C. difficile CDTb and/or CDTa proteins Download PDFInfo
- Publication number
- AU2013366450A1 AU2013366450A1 AU2013366450A AU2013366450A AU2013366450A1 AU 2013366450 A1 AU2013366450 A1 AU 2013366450A1 AU 2013366450 A AU2013366450 A AU 2013366450A AU 2013366450 A AU2013366450 A AU 2013366450A AU 2013366450 A1 AU2013366450 A1 AU 2013366450A1
- Authority
- AU
- Australia
- Prior art keywords
- seq
- protein
- cdtb
- cdta
- immunogenic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1223342.5A GB201223342D0 (en) | 2012-12-23 | 2012-12-23 | Immunogenic composition |
| GB1223342.5 | 2012-12-23 | ||
| PCT/EP2013/077762 WO2014096393A1 (en) | 2012-12-23 | 2013-12-20 | Immunogenic composition comprising elements of c. difficile cdtb and/or cdta proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2013366450A1 true AU2013366450A1 (en) | 2015-07-23 |
Family
ID=47682553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013366450A Abandoned AU2013366450A1 (en) | 2012-12-23 | 2013-12-20 | Immunogenic composition comprising elements of C. difficile CDTb and/or CDTa proteins |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9669083B2 (https=) |
| EP (1) | EP2934579B1 (https=) |
| JP (1) | JP6515036B2 (https=) |
| CN (1) | CN105120892B (https=) |
| AR (1) | AR094275A1 (https=) |
| AU (1) | AU2013366450A1 (https=) |
| BR (1) | BR112015014727B8 (https=) |
| CA (1) | CA2894951C (https=) |
| ES (1) | ES2748054T3 (https=) |
| GB (1) | GB201223342D0 (https=) |
| SG (1) | SG11201504701UA (https=) |
| WO (1) | WO2014096393A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2753352T5 (pl) | 2010-09-03 | 2022-10-17 | Valneva Austria Gmbh | Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania |
| TWI815599B (zh) | 2011-04-22 | 2023-09-11 | 美商惠氏有限責任公司 | 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法 |
| WO2013084071A2 (en) * | 2011-12-08 | 2013-06-13 | Novartis Ag | Clostridium difficile toxin-based vaccine |
| BR122016023101B1 (pt) * | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| BE1022949B1 (fr) * | 2014-06-25 | 2016-10-21 | Glaxosmithkline Biologicals S.A. | Composition immunogene |
| MX2019010948A (es) * | 2017-03-15 | 2020-01-09 | Novavax Inc | Métodos y composiciones para inducir respuestas inmunitarias contra clostridium difficile. |
| US10933126B2 (en) | 2018-05-03 | 2021-03-02 | The Board Of Regents Of The University Of Oklahoma | Clostridium difficile immunogenic compositions and methods of use |
| US12076352B2 (en) | 2018-06-19 | 2024-09-03 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| CN111793130B (zh) * | 2019-03-20 | 2021-09-14 | 华中农业大学 | 一株副猪嗜血杆菌CdtB杂交瘤细胞及单克隆抗体应用 |
| WO2021022033A1 (en) | 2019-07-30 | 2021-02-04 | Leung Kai P | Layered composite for scar treatment and prevention |
| WO2021255690A2 (en) | 2020-06-19 | 2021-12-23 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
| GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
| WO2025029561A2 (en) * | 2023-07-28 | 2025-02-06 | University Of South Florida | Vaccine containing rbd2 of cdtb component from binary toxin cdt of clostridioides difficile |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2656850T3 (es) * | 2009-02-11 | 2018-02-28 | Cedars-Sinai Medical Center | Diagnóstico del síndrome intestinal inflamatorio con base en la toxina de distensión citoletal |
| US10046040B2 (en) * | 2009-11-16 | 2018-08-14 | University Of Maryland, Baltimore | Multivalent live vector vaccine against Clostridium difficile-associated disease |
| PL2753352T5 (pl) * | 2010-09-03 | 2022-10-17 | Valneva Austria Gmbh | Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania |
| AR089797A1 (es) | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
-
2012
- 2012-12-23 GB GBGB1223342.5A patent/GB201223342D0/en not_active Ceased
-
2013
- 2013-12-20 ES ES13817931T patent/ES2748054T3/es active Active
- 2013-12-20 CN CN201380073503.5A patent/CN105120892B/zh active Active
- 2013-12-20 WO PCT/EP2013/077762 patent/WO2014096393A1/en not_active Ceased
- 2013-12-20 AU AU2013366450A patent/AU2013366450A1/en not_active Abandoned
- 2013-12-20 JP JP2015548649A patent/JP6515036B2/ja not_active Expired - Fee Related
- 2013-12-20 EP EP13817931.2A patent/EP2934579B1/en active Active
- 2013-12-20 US US14/653,989 patent/US9669083B2/en active Active
- 2013-12-20 SG SG11201504701UA patent/SG11201504701UA/en unknown
- 2013-12-20 BR BR112015014727A patent/BR112015014727B8/pt not_active IP Right Cessation
- 2013-12-20 AR ARP130105022A patent/AR094275A1/es unknown
- 2013-12-20 CA CA2894951A patent/CA2894951C/en active Active
-
2017
- 2017-05-15 US US15/595,651 patent/US20180043005A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US9669083B2 (en) | 2017-06-06 |
| JP6515036B2 (ja) | 2019-05-15 |
| GB201223342D0 (en) | 2013-02-06 |
| US20180043005A1 (en) | 2018-02-15 |
| BR112015014727B1 (pt) | 2022-08-02 |
| BR112015014727B8 (pt) | 2022-09-20 |
| CN105120892A (zh) | 2015-12-02 |
| CA2894951C (en) | 2023-05-09 |
| CN105120892B (zh) | 2020-07-31 |
| AR094275A1 (es) | 2015-07-22 |
| SG11201504701UA (en) | 2015-07-30 |
| BR112015014727A2 (pt) | 2017-10-10 |
| JP2016504993A (ja) | 2016-02-18 |
| EP2934579A1 (en) | 2015-10-28 |
| EP2934579B1 (en) | 2019-08-07 |
| US20150313985A1 (en) | 2015-11-05 |
| CA2894951A1 (en) | 2014-06-26 |
| ES2748054T3 (es) | 2020-03-12 |
| WO2014096393A1 (en) | 2014-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2934579B1 (en) | Immunogenic composition comprising elements of c. difficile cdtb and/or cdta proteins | |
| JP5922074B2 (ja) | 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ）ポリペプチドおよびその融合物を含む免疫原性組成物 | |
| EP2637687B1 (en) | Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis | |
| WO2007079684A1 (fr) | Proteines de fusion de mycobacterium tuberculosis et utilisations | |
| RS55707B1 (sr) | Izolovani polipeptid toksin a i toksin b proteina c. difficile i njihova upotreba | |
| JP2016502551A (ja) | 免疫原性組成物 | |
| EP2978447B1 (en) | Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis | |
| BR112019004913B1 (pt) | Vacinas que compreendem polipeptídeos de mycobacterium leprae para a prevenção, tratamento e diagnóstico de lepra | |
| WO2010064243A1 (en) | GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS | |
| JP2020100625A (ja) | クロストリジウム・ディフィシル免疫原性組成物 | |
| JP2015528457A (ja) | Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質 | |
| EP2838990A1 (en) | Recombinant mycobacterium encoding a heparin-binding hemagglutinin (hbha) fusion protein and uses thereof | |
| WO2014160985A2 (en) | Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis | |
| CA2952118C (en) | Clostridium difficile immunogenic composition | |
| JP2015532594A (ja) | Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質 | |
| WO2009053723A1 (en) | Small protective epitopes of the yersinia pestis v antigen and dna vaccines encoding these |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |